arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Amneal Pharmaceuticals, Inc.

AMRX

$18.15 ▲ +0.07 (+0.39%) at close

10 Visible periods

31 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Fair

Neutral

auto_awesome

Analytical Summary

Amneal Pharmaceuticals, Inc. demonstrates solid fundamentals with strength in Debt to Equity. Consider comparing against peers in the Healthcare sector before making investment decisions.

Market Cap $5.7B

Dividend Yield —

Revenue Growth 8.0% ↘

Op. Margin 13.1% ↗

ROIC 14.5% →

FCF / Share $0.86 ↗

Trailing P/E 78.9x

Price / Book —

FCF Yield 4.8%

Debt / Equity -36.33

info Valuation on last close. End-of-day price, Aug 7, 2026.

10-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$3.02B

↑ +8.0% —

Net Income Profit after all expenses

$72.06M

↑ +161.6% —

Operating Margin Operating profit as % of sales

13.1%

↑ +46.3% 63th

FCF / Share Free cash flow per share

$0.86

↑ +9.4% —

Long-Term Debt Long-term obligations

$2.57B

↑ +7.8% —

trending_up

Bullish Indicators

Debt to EquityDebt to Equity is in the top quartile (lower is better)

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability ↑

Returns

Financial Health ↑

Cash Quality ↓

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗
Revenue Growth YoY (%)	8.0% Fair ↓ Fair Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: At sector avg	16.7% Good ↑ Good Improving Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+109%)	8.2% Fair ↓ Fair Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: At sector avg	5.7% Fair ↓ Fair Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-29%)	5.1% Fair ↓ Fair Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-37%)	22.5% Excellent ↑ Excellent Improving Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+181%)	-2.2% Weak ↓ Weak Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-128%)	60.9% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+661%)	1.5% Caution Caution Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-81%)	—
EPS Growth YoY (%)	N/M	20.8% Good ↑ Good Improving Year-over-year change in earnings per share Optimal: > 10%	44.2% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	N/M	-88.7% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	N/M	—	—	—	—
Net Income Growth YoY (%)	N/M	-47.5% Weak ↓ Weak Declining Year-over-year change in net income	70.7% Excellent Excellent Year-over-year change in net income	N/M	-80.6% Weak Weak Year-over-year change in net income	N/M	-1733.0% Weak Weak Year-over-year change in net income	—	—	—
FCF Growth YoY (%)	9.4% Fair ↓ Fair Declining Year-over-year change in free cash flow	-54.2% Weak ↓ Weak Declining Year-over-year change in free cash flow	1286.2% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	-90.5% Weak Weak Year-over-year change in free cash flow	-40.4% Weak Weak Year-over-year change in free cash flow	N/M	—	—	—	—
Revenue CAGR 3Y (%)	10.9% Good ↑ Good Improving Compound annual revenue growth over 3 years	10.1% Good ↑ Good Improving Compound annual revenue growth over 3 years	6.3% Fair ↓ Fair Declining Compound annual revenue growth over 3 years	10.8% Good ↓ Good Declining Compound annual revenue growth over 3 years	8.0% Fair ↓ Fair Declining Compound annual revenue growth over 3 years	24.5% Excellent Excellent Compound annual revenue growth over 3 years	16.9% Excellent Excellent Compound annual revenue growth over 3 years	—	—	—
Revenue CAGR 5Y (%)	8.7% Good ↓ Good Declining Compound annual revenue growth over 5 years	11.4% Good ↓ Good Declining Compound annual revenue growth over 5 years	7.6% Fair ↓ Fair Declining Compound annual revenue growth over 5 years	16.4% Excellent Excellent Compound annual revenue growth over 5 years	15.5% Excellent Excellent Compound annual revenue growth over 5 years	—	—	—	—	—

💰 Are margins durable? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗
Operating Margin (%) (%)	13.1% Fair ↑ Fair Improving Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-13%)	8.9% Caution ↑ Caution Improving Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-41%)	8.5% Caution ↑ Caution Improving Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-43%)	-4.3% Weak ↓ Weak Declining Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-129%)	7.3% Caution ↑ Caution Improving Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-51%)	4.6% Weak ↑ Weak Improving Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-70%)	-15.3% Weak ↓ Weak Declining Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-202%)	-1.2% Weak ↓ Weak Declining Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-108%)	23.7% Good Good Operating income as a percentage of revenue Optimal: > 15% vs Sector: Above avg (+58%)	28.0% Excellent Excellent Operating income as a percentage of revenue Optimal: > 15% vs Sector: Above avg (+87%)
Effective Tax Rate (%) (%)	8.1% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	-34.3% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	-21.0% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	-2.7% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	35.7% Weak ↓ Weak Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	291.7% Weak ↑ Weak Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	-174.0% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.7% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	1.2% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	2.5% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%
Profit Margin (%) (%)	2.4% Weak ↑ Weak Improving Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-80%)	-4.2% Weak ↑ Weak Improving Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-135%)	-3.3% Weak ↓ Weak Declining Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-128%)	-12.2% Weak ↓ Weak Declining Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-202%)	0.6% Weak ↑ Weak Improving Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-95%)	3.4% Weak ↑ Weak Improving Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-72%)	-22.3% Weak ↓ Weak Declining Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-285%)	-1.2% Weak ↓ Weak Declining Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-110%)	0.0% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-100%)	0.0% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-100%)
FCF Margin (%) (%)	8.9% Caution ↑ Caution Improving Free cash flow as a percentage of revenue Optimal: > 10%	8.7% Caution ↑ Caution Improving Free cash flow as a percentage of revenue Optimal: > 10%	12.6% Fair ↑ Fair Improving Free cash flow as a percentage of revenue Optimal: > 10%	0.8% Weak ↓ Weak Declining Free cash flow as a percentage of revenue Optimal: > 10%	9.3% Caution ↑ Caution Improving Free cash flow as a percentage of revenue Optimal: > 10%	16.2% Good ↑ Good Improving Free cash flow as a percentage of revenue Optimal: > 10%	-2.8% Weak ↓ Weak Declining Free cash flow as a percentage of revenue Optimal: > 10%	10.1% Fair ↑ Fair Improving Free cash flow as a percentage of revenue Optimal: > 10%	13.5% Fair Fair Free cash flow as a percentage of revenue Optimal: > 10%	-0.8% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%
FCF / Net Income (x)	3.75x Excellent ↑ Excellent Improving Free cash flow relative to reported net income Optimal: > 1x	-2.08x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	-3.81x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	-0.07x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	14.75x Excellent ↑ Excellent Improving Free cash flow relative to reported net income Optimal: > 1x	4.76x Excellent ↑ Excellent Improving Free cash flow relative to reported net income Optimal: > 1x	0.13x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	-8.47x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	—	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗
Return on Invested Capital (%)	14.5% Good ↑ Good Improving Return earned on debt + equity capital invested Optimal: > 10%	14.7% Good ↑ Good Improving Return earned on debt + equity capital invested Optimal: > 10%	10.1% Good ↑ Good Improving Return earned on debt + equity capital invested Optimal: > 10%	-3.3% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	3.2% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-5.7% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-23.8% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-0.6% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	16.8% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	10.7% Good ↑ Good Improving Operating profit relative to total assets Optimal: > 10%	7.1% Fair ↑ Fair Improving Operating profit relative to total assets Optimal: > 10%	5.9% Caution ↑ Caution Improving Operating profit relative to total assets Optimal: > 10%	-2.5% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	3.9% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	2.3% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-6.8% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-0.5% Weak Weak Operating profit relative to total assets Optimal: > 10%	18.3% Excellent Excellent Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	-101.8% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-779%)	107.0% Excellent ↑ Excellent Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+613%)	—	-90.7% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-704%)	3.7% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-76%)	22.4% Excellent ↑ Excellent Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+49%)	-156.0% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1140%)	-3.9% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-126%)	—	—

⚖️ Is the balance sheet risky? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗
Debt to Equity (x)	-36.33x Excellent ↓ Excellent Declining Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-6155%)	-21.84x Excellent ↓ Excellent Declining Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-3739%)	122.35x Weak ↑ Weak Improving Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Above avg (+20291%)	8.79x Weak ↓ Weak Declining Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Above avg (+1364%)	7.52x Weak ↓ Weak Declining Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Above avg (+1154%)	9.17x Weak ↑ Weak Improving Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Above avg (+1428%)	11.34x Weak Weak Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Above avg (+1790%)	5.25x Weak Weak Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Above avg (+776%)	—	—
Interest Coverage (x)	1.99x Caution ↑ Caution Improving Operating income divided by interest expense Optimal: > 5x	0.95x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	1.06x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-0.67x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	1.25x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	0.70x Weak → Weak Stable Operating income divided by interest expense Optimal: > 5x	-1.57x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-0.15x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	3.77x Fair Fair Operating income divided by interest expense Optimal: > 5x	5.63x Good Good Operating income divided by interest expense Optimal: > 5x
Net Debt (USD)	$2.29B	$2.28B	$2.33B	$2.60B	$2.46B	$2.44B	$2.48B	$2.44B	$1.37B	$-27.37M
Debt / EBITDA (x)	5.70x Weak ↑ Weak Improving Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	7.65x Weak ↑ Weak Improving Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	8.94x Weak ↑ Weak Improving Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-97.73x Excellent ↓ Excellent Declining Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	12.70x Weak ↓ Weak Declining Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	18.34x Weak ↑ Weak Improving Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-14.19x Excellent ↓ Excellent Declining Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	59.27x Weak Weak Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	5.03x Weak Weak Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	—

📊 What does each share earn? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗
Revenue per Share (USD)	$9.63	$9.04	$13.59	$14.66	$14.06	$13.51	$12.31	—	—	—
Basic EPS, GAAP (USD)	$0.23	$-0.38	$-0.48	$-0.86	$0.07	$0.62	$-2.74	—	—	—
Free Cash Flow per Share (USD)	$0.86	$0.79	$1.72	$0.12	$1.30	$2.19	$-0.34	—	—	—
Book Value per Share (USD)	$-0.23	$-0.35	$0.11	$1.98	$2.42	$2.06	$1.76	—	—	—
Tangible Book Value per Share (USD)	$-3.92	$-4.66	$-8.34	$-9.25	$-9.40	$-10.34	$-11.89	—	—	—
Basic Weighted Avg Shares (shares)	313.37M	308.98M	176.14M	150.94M	148.92M	147.44M	132.11M	—	—	—

🏦 How resilient is the balance sheet? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗
Working Capital (USD)	$1.03B	$458.04M	$531.27M	$659.02M	$842.87M	$874.64M	$659.80M	$732.79M	$475.05M	—
LT Debt (USD)	$2.57B	$2.39B	$2.42B	$2.62B	$2.71B	$2.78B	$2.63B	$2.65B	$1.44B	—
Total Equity (USD)	$-70.79M	$-109.27M	$19.78M	$298.42M	$360.34M	$303.27M	$232.01M	$504.75M	—	—

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗
Sales/Revenue/Turnover (USD)	$3.02B	$2.79B	$2.39B	$2.21B	$2.09B	$1.99B	$1.63B	$1.66B	$1.03B	$1.02B
Depreciation Expense (USD)	$57.30M	$62.60M	$66.20M	$68.10M	$60.70M	$60.42M	$63.28M	$64.42M	$41.96M	$29.31M
Net Income, GAAP (USD)	$72.06M	$-116.89M	$-79.27M	$-270.58M	$13.16M	$67.79M	$-361.92M	$-19.74M	$0.00	$0.00
Operating Cash Flow (USD)	$339.99M	$295.10M	$345.58M	$65.10M	$241.82M	$379.00M	$1.71M	$250.23M	$234.19M	$115.06M

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 10 years · 38 quarters

Amneal Pharmaceuticals, Inc.

Analytical Summary

10-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare AMRX with peers